Jianlong Li

Dr. Jianlong Li

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2016 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JLJianlong Li
Jianlong Li
JCJinquan Cai
Jinquan Cai
ZHZhao Hong
Zhao Hong
KYKun Yao
Kun Yao
YSYing Sun
Ying Sun
CJchuanlu jiang
chuanlu jiang
The aim of this study was to investigate the effect of downregulating Hedgehog pathway by GANT61 on human glioma cells, examine the consequent changes of temozolomide (TMZ)-induced effects and explore the molecular mechanisms. The cytotoxicity of a Gli1/2 inhibitor, GANT61 was examined both alone and in combination with TMZ in human glioma cell lines. The mRNA and protein expression alterations were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot, respectively. CCK-8 assay detected the cell proliferative capability. Apoptotic cell number was measured by flow cytometry. The transwell assay was used to test the cell invasive capability. DNA damage effect was identified by COMET assay and γH2AX expression. Proliferation of tumor cells treated with GANT61 in combination with TMZ was significantly suppressed compared with those treated with either drug used alone. The combination treatment induced a higher rate of apoptosis, DNA damage and reduced the invasive capability of glioma cells. DNA damage repair enzyme MGMT and the Notch1 pathway increased in the cells treated by TMZ treatment. However, GANT61 could abrogated the protein increasing. GANT61 sensitizes glioma cells to TMZ treatment by enhancing DNA damage effect, decreasing MGMT expression and the Notch1 pathway.

20 December 2024 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
YYYufan Yang
Yufan Yang
ZLZiyuan Liu
Ziyuan Liu
YWYerong Wei
Yerong Wei
SHShuai He
Shuai He
AGAncheng Gu
Ancheng Gu
BCBohong Cen
Bohong Cen
The inherent heterogeneity of tumor cells impedes the development of targeted therapies for specific glioblastoma (GBM) subtypes. This study aims to investigate the mesenchymal subtype of GBM to uncover detailed characteristics, potential therapeutic strategies, and improve precision treatment for GBM patients. We integrated single-cell RNA sequencing (scRNA-seq), single-nucleus assay for transposase-accessible chromatin sequencing (snATAC-seq), and bulk RNA sequencing datasets to identify core gene modules, candidate therapeutic drugs, and key transcription factors specific to mesenchymal subtype GBM tumor cells which we validated in vitro and human samples. Our analysis encompassed a heterogeneous single-cell landscape of 55,845 cells from tumor and adjacent normal tissues, focusing on the mesenchymal subtype’s adverse prognosis and its association with hypoxia. We identified a core gene module composed of 38 genes and, through pharmacogenomic analysis, found that Trametinib and Dasatinib exhibit increased effectiveness against mesenchymal subtype GBM cells. Furthermore, by incorporating snATAC-seq data, we delineated a crucial regulatory network and pinpointed the key transcription factor CEBPG. Our research has highlighted the strong link between the mesenchymal-like (MES-like) properties of GBM and hypoxia, providing valuable insights into candidate drugs and pivotal targets for precision treatment of the mesenchymal subtype. Graphical Abstract

22 March 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
ZLZiyuan Liu
Ziyuan Liu
YYYufan Yang
Yufan Yang
HFHaiting Fang
Haiting Fang
BCBohong Cen
Bohong Cen
YFYiqi Fan
Yiqi Fan
SHShuai He
Shuai He
Therapeutic strategies aiming at the tumor immune microenvironment (TIME) hold promise for glioblastoma (GBM) treatment. However, adjuvant immunotherapies targeting checkpoint inhibitors just prove effective for a selected group of GBM patients. The extensive involvement of GBM-associated macrophages highlights their potential role in tumor behavior. In-depth exploration of the impact of macrophages on the efficacy of immunotherapy is crucial for enhancing treatment outcomes. In this study, we conducted a comprehensive analysis using bulk RNA-seq, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics to explore the heterogeneity of tumor-associated macrophages (TAMs) in GBM. Flow cytometry was employed to investigate the effects of VSIG4 on TAM phenotypes, and co-culture cellular assays were performed to evaluate its contribution to GBM malignancy. Integrating 16 patient samples, we examined the immunological significance of VSIG4+S100A10+TAMs. VSIG4 expression on macrophages is significantly upregulated and correlated with the TIME, promoting the polarization of macrophages towards M2 and facilitating GBM progression. Spatial transcriptomics and human samples multiplex immunofluorescence (mIF) confirmed the co-localization of VSIG4+S100A10+TAMs with various T cells, resulting in the inhibition of T cell immune responses and a reduction in anti-tumor immunity. Our findings demonstrate for the first time that VSIG4+S100A10+TAM is an independent prognostic indicator of poor outcome for GBM and markedly accumulates in patients exhibiting non-responsiveness to anti-PD-1 immunotherapy. Targeting this specific bifunctional subgroup can potentially open up new avenues for the immunotherapy of GBM.

27 February 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YDYingjie Duan
Yingjie Duan
ZPZhong Peng
Zhong Peng
SZShuzhu Zhong
Shuzhu Zhong
PZPeng Zhou
Peng Zhou
HHHong Huang
Hong Huang
ZHZhangxiu He
Zhangxiu He

5 April 2025 in Biology Direct
Verified
Journal Article
Open access
PDF file
YYYufan Yang
Yufan Yang
ZLZiyuan Liu
Ziyuan Liu
ZWZhongliang Wang
Zhongliang Wang
XFXiang Fu
Xiang Fu
ZLZhiyong Li
Zhiyong Li
BCBohong Cen
Bohong Cen
Neutrophils play a key role in the tumor microenvironment (TME); however, their functions in glioblastoma (GBM) are overlooked and insufficiently studied. A detailed analysis of GBM-associated neutrophil (GBMAN) subpopulations may offer new insights and opportunities for GBM immunotherapy. We analyzed single-cell RNA sequencing (scRNA-seq) data from 127 isocitrate dehydrogenase (IDH) wild-type GBM samples to characterize the GBMAN subgroups, emphasizing developmental trajectories, cellular communication, and transcriptional networks. We implemented 117 machine learning combinations to develop a novel risk model and compared its performance to existing glioma models. Furthermore, we assessed the biological and molecular features of the GBMAN subgroups in patients. From integrated large-scale scRNA-seq data (498,747 cells), we identified 5,032 neutrophils and classified them into four distinct subtypes. VEGFA+GBMAN exhibited reduced inflammatory response characteristics and a tendency to interact with stromal cells. Furthermore, these subpopulations exhibited significant differences in transcriptional regulation. We also developed a risk model termed the “VEGFA+neutrophil-related signature” (VNRS) using machine learning methods. The VNRS model showed higher accuracy than previously published risk models and was an independent prognostic factor. Additionally, we observed significant differences in immunotherapy responses, TME interactions, and chemotherapy efficacy between high-risk and low-risk VNRS score groups. Our study highlights the critical role of neutrophils in the TME of GBM, allowing for a better understanding of the composition and characteristics of GBMAN. The developed VNRS model serves as an effective tool for evaluating the risk and guiding clinical treatment strategies for GBM. Not applicable. Large-scale scRNA-seq of GBM identified four neutrophil subtypes and characterized their molecular landscape. Trajectory analysis identified the developmental process of MNDA+GBMAN into VEGFA+GBMAN. VEGFA+GBMAN exhibits significant immunosuppressive and hypoxic characteristics. A VNRS prognostic model based on VEGFA+GBMAN was proposed using 117 machine learning combinations. The VNRS model demonstrates significant superiority and can accurately predict patient characteristics.

21 October 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CXCuiying Xie
Cuiying Xie
JWJieyi Wu
Jieyi Wu
HYHan Yang
Han Yang
AGAncheng Gu
Ancheng Gu
WCWanwen Cao
Wanwen Cao
BCBohong Cen
Bohong Cen
Radiation resistance in glioblastoma (GBM) poses a persistent clinical hurdle, driven in part by hyperactivated EGFR and NF-κB signaling. To recapitulate post-radiation tumor recurrence, we engineered radioresistant glioblastoma stem cells (GSCs) from U87-derived GSCs via 13 cycles of 5Gy irradiation (IR), yielding differentiated radioresistant progeny cells (Diff) that mimic the aggressive phenotype of recurrent GBM. Integrative analysis of RNA sequencing data from parental U87 cells, GSCs, and Diff cells—along with the TCGA database—identified coordinated EGFR and NF-κB (RelA/p65) signaling as central mediators of therapeutic resistance. Leveraging this insight, we designed iRGD-modified liposomes (iRGD-OB-LP) for targeted co-delivery of Osimertinib (EGFR inhibitor) and Bortezomib (NF-κB suppressor). These liposomes exhibited enhanced tumor penetration, sustained release kinetics, and dual pathway inhibition, which collectively prolonged radiation-induced DNA damage, attenuated cancer stemness, and amplified apoptotic cell death. In vivo, iRGD-OB-LP achieved tumor-specific biodistribution, synergized with radiotherapy to suppress tumor progression, and extended survival without systemic toxicity. By bridging a radioresistant GBM model with mechanism-driven nanotherapy, this work provides a translatable blueprint for dismantling therapeutic resistance in GBM through precision multi-targeting.